Hovione Reports Significant Sales Growth
Hovione recently announced that the consolidated sales for the fiscal year ended March 2012 amounted to $180 million, the sixth consecutive year of sales growth, representing a growth of 24% in relation to last year.
“Another year of continued strong performance by the Hovione group. During the last 5 years, Hovione has doubled its sales and has made bold strategic steps to both strengthen its ability to serve innovators and to consolidate its leadership in off-patent contrast agents. Looking forward, and despite the difficult economic environment, we remain confident that 2012 will be another year of solid growth,” said Miguel Calado, Chief Financial Officer.
In addition to the financial results, which reflect the quality of the Team’s performance, overall, 2011 represented a year of great achievements, namely Hovione stood behind three NDA approvals (these were all major NMEs) and in two cases, the approvals were full QbD filings in which Hovione was central to the design and data generation.
All Hovione plants underwent several successful GMP inspections by one or more of the major Medicines’ Agencies – a reflection of the large flow of filings and the high standards of compliance.
“Getting multiple NDA approvals every year is becoming a habit at Hovione, which reflects well both on our customers, on our team, and on the CMO model. Our patient investment in capacity, new technologies, and development methodologies is paying off.” said Guy Villax, Chief Executive Officer.
Hovione is a global company with over 50 years’ experience in Active Pharmaceutical Ingredient and Intermediate Drug Product development and compliant manufacture. With four FDA-inspected sites in the
For more information, contact Marketing & Communications, Isabel Pina, at 351 21 982 9362, email ipina@hovione.com, or visit www.hovione.com.
Total Page Views: 1082
